Navigation Links
Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Date:11/12/2009

onsider past results to be an indication of our future performance. For a discussion of the risk factors and other factors that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law. We plan to provide a material update to this ongoing Phase I study in the form of this poster presentation.

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCY
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye, today ... 2014 Medical Technology & Diagnostics Forum in ... on Thursday, November 20 at 12:30 p.m. PT/3:30 p.m. ... overview of the Company,s current business trends, financial results, ...
(Date:11/17/2014)... Calif. , Nov. 17, 2014 Asterias ... in the emerging field of regenerative medicine, today announced ... of Research and Development, will participate in a live ... Regenerative Medicine (CIRM) discussing the latest progress in stem ... The CIRM Google Hangout session is scheduled for Tuesday, ...
(Date:11/17/2014)... 17, 2014  CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... investor conferences. Jefferies 2014 Global Healthcare Conference ... EST, London, England . ... December 3 at 9:00 a.m. EST, New York, ... webcast live and available for replay after the presentation. The webcast ...
Breaking Medicine Technology:STAAR Surgical To Present At The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum 2Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury 2CTI BioPharma to Present at the Upcoming Investor Conferences 2
... Edge EHR Corp., EDGE, a provider of Dental ... to announce the release of edgeDMS™ for ... leverage the awesome power of the Apple® iPad. ... (Logo:   http://photos.prnewswire.com/prnh/20100310/AQ68604LOGO ) The ...
... Calif., Dec. 21, 2010 Jazz Pharmaceuticals, Inc. (Nasdaq: ... States Patent and Trademark Office (USPTO) has issued a ... "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for ... is also listed in the FDA,s Approved Drug Products ...
Cached Medicine Technology:Edge EHR Corp. Announces edgeDMS for iPad, Native Touch-Based Clinical Charting Software for the Paperless Dental Office. 2Jazz Pharmaceuticals Announces New Patent Issued for Sodium Oxybate 2
(Date:11/18/2014)... Cristcot Inc., a global life sciences ... specialized drug delivery systems, today announced that the ... for the technology, which encompasses the company’s commercially ... patent was awarded to the inventor Jennifer Davagian ... to Cristcot Inc. The patented technology, titled “Method ...
(Date:11/18/2014)... Medicationdiscountcard.com's blog offers health ... company's reputation for helping consumers save money at ... offer at http://blog.medicationdiscountcard.com/ . , Consumers need ... Affordable Care Act and the state health benefit ... about a variety of prescription drug and health ...
(Date:11/18/2014)... HealthDay Reporter MONDAY, Nov. 17, ... prove effective at lowering LDL ("bad") cholesterol levels for ... That,s the conclusion of a clinical trial presented ... Chicago. The drug, alirocumab, outperformed the on-the-market medication ... statins, Zetia, said lead researcher Dr. Patrick Moriarty, director ...
(Date:11/18/2014)... 2014 (HealthDay News) -- Women who started smoking at ... chronic, severe menstrual pain, a new study suggests. ... While smoking has been suspected as a risk factor ... the authors of the new study said. The ... a long-term study of women,s health in Australia. About ...
(Date:11/18/2014)... 18, 2014 Global Partnership ... the telehealth platform to bring quality healthcare to ... passion, GPT created Global Partnership for TeleHealth Missions ... existing telehealth network. GPTM focuses specifically on ... and disaster relief organizations. , Michael ...
Breaking Medicine News(10 mins):Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Medicationdiscountcard.com Building Virtual Library of Resources to Help Consumers Navigate Healthcare Landscape 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Global Partnership for TeleHealth (GPT) is Focused on Using the telehealth Platform to Bring Quality Healthcare to Populations in Need Worldwide 2
... a History of Eating Disorders More at Risk for ... for Eating and Anxiety Disorders ( www.remudaranch.com ), the ... new pressure to look perfect while pregnant. "With the ... an increased pressure to look perfect and thin during ...
... is the only authorized online learning program ... Known for bringing innovation to the chiropractic ... only web-based seminar program dedicated exclusively to ... Online, the online learning system authorized by ...
... 19 Abbott announced today,that the U.S. ... the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for ... analyzer. , Cartridges for E3+, ... patient,s,metabolic state within a few minutes. The glucose ...
... Amazing Heat Pack by Comfort Now, Inc., a revolutionary ... pain relief for athletes, arthritics, chronic pain sufferers, premenstrual ... musclesBURLINGTON, Ontario, Jan. 19 Not since the 1920 ... aid product been released as The Amazing Heat Pack, ...
... Commitment to Healthy and Successful Vascular Access for ... Vascular Access(SM), the nation,s leading provider of vascular ... of managed vascular access centers has collectively ,touched, ... Lifeline Vascular Access managed center Nephrology Vascular Lab ...
... The 2008 Frost & Sullivan Technology Innovation Award ... presented to TECNIMED srl for pioneering THERMOFOCUS, the first ... available with a new, rapid, room temperature stabilization system. ... the company that has demonstrated technological superiority within its ...
Cached Medicine News:Health News:Remuda Ranch Reports More Women Seek to Be Thin During Pregnancy 2Health News:Activator Methods Introduces Web-Based Seminar Program 2Health News:Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer 2Health News:Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer 3Health News:The Amazing Heat Pack: The Most Innovative First Aid Solution Since the Band-Aid 2Health News:Lifeline Vascular Access Treats a Quarter Million Patients 2Health News:Lifeline Vascular Access Treats a Quarter Million Patients 3Health News:TECNIMED Picks Up Frost & Sullivan Award for its Innovative THERMOFOCUS 2Health News:TECNIMED Picks Up Frost & Sullivan Award for its Innovative THERMOFOCUS 3Health News:TECNIMED Picks Up Frost & Sullivan Award for its Innovative THERMOFOCUS 4
... The Vitros 250 is ... meet requirements in multiple environments ... large hospitals, clinics and satellite ... features on-board dilution, and can ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Architect i2000 is a flexible solution for your evolving laboratory providing high throughput and walkaway time with built-in flexibility....
... The Bayer Immuno 1 provides ... immunoassay instrument with over 50 ... endocrinology, tumor marker, therapeutic drug, ... can be performed on a ...
Medicine Products: